Welcome to our dedicated page for Provectus Biopha SEC filings (Ticker: PVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Provectus Biopharmaceuticals filings document governance, capital-structure actions, and material-event disclosures for a clinical-stage biotechnology issuer focused on rose bengal sodium-based medicines. Proxy materials cover annual-meeting voting matters, board elections, stock ownership, director and officer interests, and related-party transaction disclosures.
Form 8-K reports record corporate events such as annual-meeting announcements and amendments to the certificates of designation for Series D and Series D-1 Convertible Preferred Stock. These filings also describe preferred-stock conversion terms, common-stock implications, exhibit filings, and the company’s use of press releases to furnish updates tied to public-company reporting.
Provectus Biopharmaceuticals, Inc. held its annual stockholder meeting on June 18, 2026, where five proposals were decided. Stockholders elected four directors to one‑year terms, with each nominee receiving over 191 million votes in favor, plus 131,619,889 broker non‑votes reported on this item.
They approved an advisory vote on executive compensation, with 190,162,705 votes for and 16,667,960 against, and ratified CBIZ CPAs P.C. as independent registered public accounting firm for 2026 with 329,742,597 votes for. Stockholders also authorized the board to implement a reverse stock split of common and certain preferred stock at a ratio between 1‑for‑10 and 1‑for‑50, and to proportionally reduce authorized common and preferred shares using the same ratio once selected by the board.
Provectus Biopharmaceuticals, Inc. filed a current report describing information to be shared at its June 18, 2026 annual meeting of stockholders. The company plans to update stockholders on clinical development, regulatory affairs, drug discovery, manufacturing, intellectual property, business development, and corporate development activities.
The accompanying 2026 Annual Meeting of Stockholders presentation slides are attached as Exhibit 99.1. This material is furnished under Regulation FD and is not deemed filed under the Securities Exchange Act of 1934.
PROVECTUS BIOPHARMACEUTICALS, INC. director and CEO Edward Pershing exercised convertible securities to increase his common stock holdings. On the transactions date, an 8% unsecured convertible promissory note converted into 9,436 shares of Series D-1 Convertible Preferred Stock at $2.862 per preferred share. Each preferred share is convertible into 10 shares of common stock, resulting in 94,360 additional common shares. After these derivative exercises and conversions, Pershing directly owns 2,857,285 shares of common stock. These were conversions of existing securities, not open-market purchases or sales.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported receiving an 8% unsecured convertible promissory note as a derivative award. The note can be converted into Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share, with 5,242 preferred shares issuable on conversion. The note’s principal and interest will automatically convert into Series D-1 Preferred Stock twelve months after its issue date. Each Series D-1 Preferred share is itself convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028, unless converted earlier under its terms.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing exercised derivative securities to acquire additional common stock. An 8% unsecured convertible promissory note converted into 32,089 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share, then those preferred shares converted into 320,890 shares of common stock. Following these conversions, Pershing directly holds 2,847,849 shares of common stock. These were non‑market derivative conversions, not open‑market purchases or sales.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing reported a non-market transaction that increases his common stock position through derivative conversions. An 8% unsecured convertible promissory note was converted into 22,651 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share, as described in the financing terms. Each preferred share is convertible into 10 shares of common stock, resulting in 226,510 common shares underlying this conversion. Following these exercises and conversions, Pershing directly holds 2,815,760 shares of common stock, reflecting a larger equity stake obtained through previously agreed financing and conversion features rather than open-market purchases.
Provectus Biopharmaceuticals, Inc. reported a net loss of $1.3 million for the three months ended March 31, 2026, compared with $1.16 million a year earlier. Grant revenue fell from $278,628 to zero as a prior Tennessee grant was fully recognized in 2025.
Research and development expenses declined 17.2% to $333,334, and general and administrative costs decreased 6.1% to $914,569, reflecting lower clinical activity, professional fees, and stock-based compensation, partly offset by higher legal and software costs. Cash was $223,883 at March 31, 2026, with a working capital deficit of $6.78 million and an accumulated deficit of $264.1 million.
The company discloses that these conditions raise substantial doubt about its ability to continue as a going concern and states it must secure additional financing, including through its 2025 unsecured convertible notes program, equity offerings, or collaborations to fund operations and planned clinical development of its RBS-based drug candidates.
PROVECTUS BIOPHARMACEUTICALS, INC. CEO Edward Pershing exercised derivative securities related to prior financing arrangements. An 8% unsecured convertible promissory note converted into 18,876 shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per preferred share. Each preferred share is convertible into 10 shares of common stock, resulting in 188,760 shares of common stock. Following these conversions, Pershing held 2,793,109 shares of common stock directly, with no remaining derivative position from this note.
Provectus Biopharmaceuticals, Inc. is asking stockholders to approve several key corporate and governance items at its 2026 annual meeting. The in‑person meeting is scheduled for June 18, 2026 in Knoxville, Tennessee, with a record date of April 20, 2026.
Stockholders will vote to elect four directors, approve on an advisory basis the compensation of named executive officers, and ratify CBIZ CPAs P.C. as independent auditor for 2026. The proxy details executive pay, including 2025 base salaries of $240,000 for the CEO and President and $200,000 for the CFO, plus prior large stock option grants under the 2024 Equity Compensation Plan.
The most structural proposals would authorize the board to implement a reverse stock split of common stock, Series D Preferred, and Series D‑1 Preferred at a ratio between 1‑for‑10 and 1‑for‑50, and, only if that split is approved, to proportionally reduce authorized common and preferred shares. As of the record date, there were 420,279,879 common shares outstanding, along with 956,985 Series D and 14,389,027 Series D‑1 shares. The board unanimously recommends voting “FOR” all five proposals.